EP3897868A1 - Nouvelles utilisations cosmétiques et dermatologiques d'un extrait de cistus monspeliensis - Google Patents
Nouvelles utilisations cosmétiques et dermatologiques d'un extrait de cistus monspeliensisInfo
- Publication number
- EP3897868A1 EP3897868A1 EP19842805.4A EP19842805A EP3897868A1 EP 3897868 A1 EP3897868 A1 EP 3897868A1 EP 19842805 A EP19842805 A EP 19842805A EP 3897868 A1 EP3897868 A1 EP 3897868A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- extract
- skin
- cistus
- monspe
- iensis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 209
- 239000002537 cosmetic Substances 0.000 title claims abstract description 58
- 241000372914 Cistus monspeliensis Species 0.000 title claims abstract description 44
- 235000005238 Cistus monspeliensis Nutrition 0.000 title claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 57
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 48
- 210000004400 mucous membrane Anatomy 0.000 claims abstract description 44
- 230000001965 increasing effect Effects 0.000 claims abstract description 34
- 230000014509 gene expression Effects 0.000 claims abstract description 33
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 30
- 102100031758 Extracellular matrix protein 1 Human genes 0.000 claims abstract description 22
- 101000866526 Homo sapiens Extracellular matrix protein 1 Proteins 0.000 claims abstract description 21
- 230000004888 barrier function Effects 0.000 claims abstract description 19
- 230000024245 cell differentiation Effects 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 18
- 230000030968 tissue homeostasis Effects 0.000 claims abstract description 18
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 12
- 230000000699 topical effect Effects 0.000 claims abstract description 11
- 231100000241 scar Toxicity 0.000 claims abstract description 6
- 208000032544 Cicatrix Diseases 0.000 claims abstract description 5
- 230000037387 scars Effects 0.000 claims abstract description 5
- 206010024434 Lichen sclerosus Diseases 0.000 claims abstract description 4
- 230000009467 reduction Effects 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 53
- 239000002904 solvent Substances 0.000 claims description 37
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 16
- 210000001519 tissue Anatomy 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 241000984090 Cistus Species 0.000 claims description 13
- 235000002548 Cistus Nutrition 0.000 claims description 13
- 210000004209 hair Anatomy 0.000 claims description 10
- 210000004761 scalp Anatomy 0.000 claims description 9
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 201000004384 Alopecia Diseases 0.000 claims description 7
- 230000018044 dehydration Effects 0.000 claims description 7
- 238000006297 dehydration reaction Methods 0.000 claims description 7
- 208000024963 hair loss Diseases 0.000 claims description 7
- 230000003676 hair loss Effects 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 229920005862 polyol Polymers 0.000 claims description 6
- 150000003077 polyols Chemical class 0.000 claims description 6
- 210000002414 leg Anatomy 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 210000000689 upper leg Anatomy 0.000 claims description 4
- 210000001015 abdomen Anatomy 0.000 claims description 3
- 239000006286 aqueous extract Substances 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 208000008892 Lipoid Proteinosis of Urbach and Wiethe Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 92
- 241000196324 Embryophyta Species 0.000 description 24
- 238000000605 extraction Methods 0.000 description 24
- 150000003839 salts Chemical class 0.000 description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 210000002615 epidermis Anatomy 0.000 description 15
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 12
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 11
- 210000002510 keratinocyte Anatomy 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000006071 cream Substances 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 235000010443 alginic acid Nutrition 0.000 description 7
- 229920000615 alginic acid Polymers 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 210000004877 mucosa Anatomy 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 239000005913 Maltodextrin Substances 0.000 description 6
- 229920002774 Maltodextrin Polymers 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 229940051250 hexylene glycol Drugs 0.000 description 6
- 229940035034 maltodextrin Drugs 0.000 description 6
- 210000002752 melanocyte Anatomy 0.000 description 6
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 description 6
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 5
- MBQDHVLINYDJHO-UHFFFAOYSA-N 5-naphthalen-1-ylpentanoic acid Chemical compound C1=CC=C2C(CCCCC(=O)O)=CC=CC2=C1 MBQDHVLINYDJHO-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 239000004166 Lanolin Substances 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 229940072056 alginate Drugs 0.000 description 4
- -1 alkali metal salts Chemical class 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 125000004494 ethyl ester group Chemical group 0.000 description 4
- LEWJAHURGICVRE-AISVETHESA-N labdane Chemical compound CC1(C)CCC[C@]2(C)[C@@H](CC[C@H](C)CC)[C@@H](C)CC[C@H]21 LEWJAHURGICVRE-AISVETHESA-N 0.000 description 4
- 229940039717 lanolin Drugs 0.000 description 4
- 235000019388 lanolin Nutrition 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000000419 plant extract Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 101150077445 Ecm1 gene Proteins 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008406 cosmetic ingredient Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 210000003780 hair follicle Anatomy 0.000 description 3
- 210000004247 hand Anatomy 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 238000002803 maceration Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titanium dioxide Inorganic materials O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- NALGVVPRJHXHNM-UHFFFAOYSA-N 5-(5,5,8a-trimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl)-3-methylpentanoic acid Chemical compound CC1(C)CCCC2(C)C(CCC(C)CC(O)=O)C(=C)CCC21 NALGVVPRJHXHNM-UHFFFAOYSA-N 0.000 description 2
- JMHFFDIMOUKDCZ-NTXHZHDSSA-N 61214-51-5 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 JMHFFDIMOUKDCZ-NTXHZHDSSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 206010001488 Aggression Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 101800005049 Beta-endorphin Proteins 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 244000000182 Helichrysum angustifolium Species 0.000 description 2
- 235000018625 Helichrysum angustifolium Nutrition 0.000 description 2
- 235000013530 Helichrysum italicum Nutrition 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000010661 Lavandula stoechas Nutrition 0.000 description 2
- 241001530572 Lavandula stoechas Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- JDRSMPFHFNXQRB-IBEHDNSVSA-N decyl glucoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JDRSMPFHFNXQRB-IBEHDNSVSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960005150 glycerol Drugs 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- KVWWIYGFBYDJQC-UHFFFAOYSA-N methyl dihydrojasmonate Chemical compound CCCCCC1C(CC(=O)OC)CCC1=O KVWWIYGFBYDJQC-UHFFFAOYSA-N 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229940068065 phytosterols Drugs 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 235000010215 titanium dioxide Nutrition 0.000 description 2
- 229940074410 trehalose Drugs 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- MCHQEVJMCLOQAZ-UHFFFAOYSA-N (13R)-labdan-8,15-diol Natural products CC1(C)CCCC2(C)C(CCC(CCO)C)C(C)(O)CCC21 MCHQEVJMCLOQAZ-UHFFFAOYSA-N 0.000 description 1
- INLFWQCRAJUDCR-IQVMEADQSA-N (1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane] Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 INLFWQCRAJUDCR-IQVMEADQSA-N 0.000 description 1
- XVULBTBTFGYVRC-FFADBYAMSA-N (1r,2r,8as)-1-[(3r)-3-hydroxy-3-methylpent-4-en-1-yl]-2,5,5,8a-tetramethyldecahydronaphthalen-2-ol Chemical compound CC1(C)CCC[C@]2(C)[C@@H](CC[C@](O)(C)C=C)[C@](C)(O)CCC21 XVULBTBTFGYVRC-FFADBYAMSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- QNZANUZIBYJBIN-XSWJXKHESA-N (3s)-3-[[(2s)-2-acetamido-5-amino-5-oxopentanoyl]amino]-4-[[(2s)-1-[[(1s)-1-carboxy-2-(1h-imidazol-5-yl)ethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound NC(=O)CC[C@H](NC(C)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 QNZANUZIBYJBIN-XSWJXKHESA-N 0.000 description 1
- RJZNPROJTJSYLC-LLINQDLYSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O RJZNPROJTJSYLC-LLINQDLYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 229940043375 1,5-pentanediol Drugs 0.000 description 1
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- QNESDXMHQYMNGD-UHFFFAOYSA-N 2,3-bis(3,5,5-trimethylhexanoyloxy)propyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CC(=O)OCC(OC(=O)CC(C)CC(C)(C)C)COC(=O)CC(C)CC(C)(C)C QNESDXMHQYMNGD-UHFFFAOYSA-N 0.000 description 1
- XFOQWQKDSMIPHT-UHFFFAOYSA-N 2,3-dichloro-6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Cl)C(Cl)=N1 XFOQWQKDSMIPHT-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- ILCOCZBHMDEIAI-UHFFFAOYSA-N 2-(2-octadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCO ILCOCZBHMDEIAI-UHFFFAOYSA-N 0.000 description 1
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- BJRXGOFKVBOFCO-UHFFFAOYSA-N 2-hydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(C)O BJRXGOFKVBOFCO-UHFFFAOYSA-N 0.000 description 1
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- MSTDXOZUKAQDRL-UHFFFAOYSA-N 4-Chromanone Chemical compound C1=CC=C2C(=O)CCOC2=C1 MSTDXOZUKAQDRL-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 101710196690 Actin B Proteins 0.000 description 1
- 102000010637 Aquaporins Human genes 0.000 description 1
- 108010063290 Aquaporins Proteins 0.000 description 1
- 244000125300 Argania sideroxylon Species 0.000 description 1
- 235000016108 Argania sideroxylon Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 1
- 241000978490 Bistorta Species 0.000 description 1
- 229930182476 C-glycoside Natural products 0.000 description 1
- 150000000700 C-glycosides Chemical class 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 244000146462 Centella asiatica Species 0.000 description 1
- 235000004032 Centella asiatica Nutrition 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 244000298479 Cichorium intybus Species 0.000 description 1
- 235000007542 Cichorium intybus Nutrition 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- XTJFFFGAUHQWII-UHFFFAOYSA-N Dibutyl adipate Chemical compound CCCCOC(=O)CCCCC(=O)OCCCC XTJFFFGAUHQWII-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- WQXNXVUDBPYKBA-UHFFFAOYSA-N Ectoine Natural products CC1=NCCC(C(O)=O)N1 WQXNXVUDBPYKBA-UHFFFAOYSA-N 0.000 description 1
- 102100030801 Elongation factor 1-alpha 1 Human genes 0.000 description 1
- 241000237537 Ensis Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 101710127949 Extracellular matrix protein 1 Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 244000153234 Hibiscus abelmoschus Species 0.000 description 1
- 235000010616 Hibiscus abelmoschus Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000920078 Homo sapiens Elongation factor 1-alpha 1 Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000557752 Khaya Species 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- KHCCSRVJJDOANA-RQOBALISSA-N Labdanolic acid Chemical compound CC1(C)CCC[C@]2(C)[C@@H](CC[C@H](C)CC(O)=O)[C@](C)(O)CC[C@H]21 KHCCSRVJJDOANA-RQOBALISSA-N 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- 108700037001 Lactoperoxidases Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 235000013939 Malva Nutrition 0.000 description 1
- 240000000982 Malva neglecta Species 0.000 description 1
- 235000000060 Malva neglecta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000544912 Melanoides Species 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-O Methylammonium ion Chemical compound [NH3+]C BAVYZALUXZFZLV-UHFFFAOYSA-O 0.000 description 1
- 241001085990 Multinervis Species 0.000 description 1
- 244000183278 Nephelium litchi Species 0.000 description 1
- 235000015742 Nephelium litchi Nutrition 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- FUHLDYZESQTORJ-UHFFFAOYSA-N OP(O)(O)=O.CCCCCCCCCCCCCCCC(O)(O)[Na] Chemical compound OP(O)(O)=O.CCCCCCCCCCCCCCCC(O)(O)[Na] FUHLDYZESQTORJ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 229920000289 Polyquaternium Polymers 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241001249696 Senna alexandrina Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 244000047670 Viola x wittrockiana Species 0.000 description 1
- 235000004031 Viola x wittrockiana Nutrition 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 244000170226 Voandzeia subterranea Species 0.000 description 1
- 235000013030 Voandzeia subterranea Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002364 anti-haemorrhagic effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000001058 brown pigment Substances 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940071160 cocoate Drugs 0.000 description 1
- 238000000658 coextraction Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 229940100539 dibutyl adipate Drugs 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 229940120503 dihydroxyacetone Drugs 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229940113120 dipropylene glycol Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 description 1
- 230000001700 effect on tissue Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940060384 isostearyl isostearate Drugs 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- KHCCSRVJJDOANA-UHFFFAOYSA-N labdanolic acid Natural products CC1(C)CCCC2(C)C(CCC(C)CC(O)=O)C(C)(O)CCC21 KHCCSRVJJDOANA-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940031674 laureth-7 Drugs 0.000 description 1
- PYIDGJJWBIBVIA-UYTYNIKBSA-N lauryl glucoside Chemical compound CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 description 1
- 229940048848 lauryl glucoside Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- SOQBVABWOPYFQZ-UHFFFAOYSA-N oxygen(2-);titanium(4+) Chemical class [O-2].[O-2].[Ti+4] SOQBVABWOPYFQZ-UHFFFAOYSA-N 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 108010049224 perlecan Proteins 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000059 polyethylene glycol stearate Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000004918 root sheath Anatomy 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 235000019719 rose oil Nutrition 0.000 description 1
- 239000010666 rose oil Substances 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 229940048730 senega Drugs 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229940083608 sodium hydroxide Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940045875 sodium pidolate Drugs 0.000 description 1
- CRPCXAMJWCDHFM-DFWYDOINSA-M sodium;(2s)-5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)[C@@H]1CCC(=O)N1 CRPCXAMJWCDHFM-DFWYDOINSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229940098760 steareth-2 Drugs 0.000 description 1
- 229940100458 steareth-21 Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 229940116962 triisononanoin Drugs 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4966—Triazines or their condensed derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- the present invention relates to the non-therapeutic or dermatological cosmetic use of an extract of the Cistus monspeliensis plant to increase and / or maintain tissue homeostasis of the skin and / or mucous membranes and / or cutaneous appendages.
- the skin is a protective organ against external aggressions such as stress, pollution, UV radiation, temperature changes. It plays a barrier role.
- Involucrine is a soluble protein synthesized at the level of keratinocytes which allows the maintenance of the stratum corneum of the skin by participating in the differentiation of the epidermis and consequently, facilitating the cohesion of the stratum corneum.
- the ECM1 protein (Extracellular Matrix Protein 1) is a secreted glycoprotein of 85 kDa playing a key role in the structure and homeostasis of the skin. She participates in the formation and recovery of the basement membrane, the differentiation of epidermal and dermal tissues during development and throughout life post ⁇ native. Its functions in humans have been highlighted by the study of skin pathologies associated with loss of function mutations in the gene coding for ECM1. It is expressed in the skin, and in the keratinocytes of the epidermis.
- ECM1 is localized in the basal layer of the epidermis, in the dermal vessels and the outer sheath of the hair follicle (ORS: outer root sheath), but also in the supra-basal layers of the epidermis.
- the ECM1 protein is also expressed in the dermis, where it binds to a multitude of structural proteins including perlecan, thus participating in the organization of basement membranes and the assembly of collagen fibers.
- ECM1 The expression of ECM1 is negatively regulated in aged skin and, conversely, is overexpressed in skin irradiated with UVs. Deficient patients ECM 1 and exposed to the sun have a skin with scars and appearance ⁇ old picture more severe compared to the unexposed skin. The presence of thick and persistent scars in pathologies deficient in ECM1 suggests an important role of this protein in repair, remodeling or the phases of tissue regeneration.
- the ECM1 protein therefore constitutes a prime target in the fields of cosmetics and dermatology, in constant demand for alternative active ingredients, in particular on the components of the extracellular matrix (ECM), active in the formation of the matrix network, of cell adhesion, regulation of tissue differentiation.
- ECM extracellular matrix
- tissue homeostasis The central involvement of this protein in tissue homeostasis makes it a prime target for the development of active ingredients for the skin, scalp and its appendages (hair, hair, nails).
- the plant C. monspe / iensis also called Ciste devier, is a plant that is commonly found in France, in North Africa, and more generally around the Mediterranean basin. It is a fragrant shrub known to quickly colonize arid and degraded land, especially after a fire. Its essential oil is known for its anti-hemorrhagic and anti ⁇ infectious properties.
- an extract of C. monspe / iensis has the ability to both increase the expression of the ECM1 protein and the involucrine protein. This extract therefore has an effect on tissue homeostasis and on the barrier function of the skin and skin appendages.
- An advantage of the extract according to the invention is that it is a topically acceptable active ingredient, which does not generate redness or allergies by application to the skin and / or mucous membranes. Another advantage of the extract according to the invention is that it is easy to produce it on an industrial scale.
- Application FR2856299 describes several species of the genus Cistus comprising labdanic compounds and their effects on the promotion of collagen synthesis.
- the extracts can thus be used to fight against wrinkles and sagging skin.
- Application FR2819718 describes several lipid plant extracts including that of C. monspe / iensis and their use in cosmetic products to combat the effects of aging. However, this application does not describe an extract from the aerial parts of C. monspe / iensis and the lipid extracts are obtained by extraction with supercritical CO 2.
- Application JP2011162504 describes an extract of C. monspe / iensis stimulating the synthesis of ATP to promote cell growth and cell division. But nowhere in this document is disclosed the use of an extract from the aerial parts of C. monspe / iensis to increase cell differentiation, and even less an extract from the aerial parts of the plant using water as the sole solvent .
- Application JP2003267865 discloses labdanic molecules present in the plant C. monspe / iensis and their use as a cellular activator.
- the present invention differs from this prior art in that the aim of the present invention is not the use of an extract of C. monspe / iensis to increase cell growth but to increase cell differentiation, allowing to increase tissue homeostasis.
- no document of the prior art discloses an extract of C. monspe / iensis, a fortiori not an extract of the aerial parts of the plant, to maintain and / or increase the barrier function of the skin.
- a first subject of the invention thus relates to the non-therapeutic cosmetic use of an extract of C. monspe / iensis for maintaining and / or increasing tissue homeostasis in the skin and / or mucous membranes and / or the appendices. skin.
- the term “cosmetic use” means a non-therapeutic use, that is to say a use which does not require a therapeutic treatment and intended for skin and / or mucous membranes and / or cutaneous appendages healthy, that is to say who do not have any pathology according to a dermatologist, who do not have infection, inflammation, scar, disease or skin condition such as candidiasis, impetigo, psoriasis, eczema, acne or dermatitis, or rosacea, or of wounds or wounds or does not suffer from lichen sclerosus or lipoido-proteinosis.
- the extract according to the invention is a topically acceptable active extract.
- topically acceptable is understood here to mean an extract suitable for topical application, non-toxic, which is not irritating to the skin and / or the mucous membranes and / or the cutaneous appendages, which does not induce an allergic response. , which is not chemically unstable.
- the use of the extract according to the invention can be by oral or topical administration.
- the extract is applied topically.
- topical route means the direct local application and / or the vaporization of the extract on the surface of the skin and / or of the mucous membranes and / or of the cutaneous appendages.
- macous membrane means the vaginal mucosa, the urogenital mucosa, the anal mucosa, the nasal mucosa, the buccal mucosa, the ocular mucosa, the labial and / or gingival mucosa, preferably the labial mucosa.
- the skin includes the scalp.
- skin appendages is understood to mean hair, body hair, nails, preferably it is hair.
- the extract according to the invention may be applied topically to all or part of the face and / or of the body and / or of the scalp and / or of the skin appendages and / or of the mucous membranes chosen from the legs, hands, thighs, belly, Vietnameselleté, neck, arms, torso, back, hair, face, especially around the eyes, advantageously neckline and / or face, especially around the eyes, advantageously around the contour eyes.
- tissue homeostasis is understood to mean maintaining the balance between the functions of exchange and synthesis of the various components at the level of the skin and / or mucous membranes and / or cutaneous appendages, advantageously at level of the epidermis, making it possible to keep the biological parameters of the skin and / or mucous membranes and / or skin appendages constant in the face of changes in the external environment.
- Tissue homeostasis will be increased and / or maintained at the level of the skin and / or mucous membranes and / or cutaneous appendices as soon as the cellular differentiation at the level of skin and / or mucous membranes and / or cutaneous appendages, and / or that the barrier function of the skin and / or of the cutaneous appendages is increased and / or maintained.
- the extract of C. monspe / iensis maintains and / or increases cell differentiation in the skin and / or mucous membranes and / or cutaneous appendages.
- the term “increase and / or maintain cell differentiation” is intended to increase the gene and / or protein expression of ECM1 in the skin and / or mucous membranes and / or cutaneous appendages.
- the extract of C. monspe / iensis is in an amount effective to increase cell differentiation when the increase in gene and / or protein expression of ECMl is at least 30%, preferably at least 40 % in the presence of the extract of C. monspe / iensis, in comparison with the level of gene and / or protein expression detected in the absence of the extract.
- the increase in the expression of ECM1 is measured in human keratinocytes qualified as "normal", that is to say not pathological, advantageously still in the presence of the extract of C. monspeliensis prepared as described in example la). Very advantageously, this will be an increase in the gene expression of ECM1 measured by quantitative PCR (Q-PCR), under the conditions as described in Example 2a). Alternatively, it could be an increase in the protein expression of ECM1 measured by Western blot, under the conditions described in Example 2b).
- the non-therapeutic cosmetic use of the extract of C. monspeliensis according to the invention is not for maintaining and / or increasing cell growth, or cell proliferation.
- the extract of C. monspeliensis according to the invention is also not for increasing cell division.
- the extract is not either for increasing and / or maintaining the synthesis of ATP.
- the term “increase the barrier function” of the skin and / or the skin appendages is understood to mean increasing the thickness of the epidermis and / or promoting the cohesion of the stratum corneum at the level of the skin and / or the skin appendages.
- the extract of C. monspeliensis according to the invention is therefore useful for reducing water loss in the skin and / or the skin appendages and / or for preventing dehydration.
- the extract of C. monspeliensis is in an amount effective to increase the barrier function when the increase in gene and / or protein expression of involucrine will be at least 50%, advantageously at least 100%, very advantageously at least 150%, in the presence of the extract of C. monspeliensis according to the invention, in comparison with the level of expression of involucrine detected without extract.
- it will be an increase in the protein expression of involucrine and still advantageously, this increase will be measured in human keratinocytes qualified as "normal", that is to say say non-pathological, preferably still in the presence of the extract of C. monspeliensis prepared as described in example la).
- this measure the increase in the protein expression of involucrine will be carried out by ELISA technique, under the conditions described in Example 3.
- increase gene expression is intended to increase the expression of the mRNAs coding for ECM1 and / or involucrine.
- increasing protein expression is meant increasing protein synthesis.
- the extract of C. monspe / iensis increases and / or maintains tissue renewal in the skin and / or mucous membranes and / or cutaneous appendages.
- tissue renewal can be assessed in vivo.
- the extract of C. monspe / iensis according to the invention is considered to be in an amount effective for "increasing tissue renewal" when a reduction of at least 2, preferably at least 3, in the number of days required at total renewal of the epidermis will be observed in the presence of the extract according to the invention, in comparison with the number of days required to renew the epidermis without extract.
- this number of days is determined after application twice a day for a total period of 28 days of a cream comprising the extract of C. monspeiiensis on the forearms of a population of women aged 45 to 65 years , compared to a placebo cream without extract.
- the number of days necessary for epidermal renewal is measured by the DHA method (Dihydroacetone), consisting in coloring the skin surface of interest with said DHA, which reacts with the proteins of the epidermis to form brown melanoid pigments.
- the necessary discoloration time for brown pigments corresponds to the renewal time considered to be total.
- the cream used comprises a final concentration of extract of C. monspeiiensis prepared according to Example 1a) of 0.1% by weight relative to the total weight of said cream, as described in Example 4 of the present request.
- the extract of C. monspeiiensis can be used in the context of the invention to improve the surface appearance of the skin and / or the skin appendages and / or mucous membranes.
- the term “improving the surface appearance” is intended to improve the texture of the skin and / or of the mucous membranes and / or of the cutaneous appendages.
- the extract of C. monspeiiensis can also be used to increase the radiance of the complexion skin.
- increasing the radiance of the complexion is meant increasing the luminosity of the skin and / or the uniformity of the complexion and / or improving the radiance and / or reducing the dull and / or earthy complexion of the skin.
- the extract of C. monspe / iensis is considered to be in an amount effective for "increasing the radiance of the complexion" when the extract decreases the overall melanin level by at least 40 %, advantageously at least 55% and still advantageously at least 60%.
- this is a measurement carried out in B16 melanocytes cultured in the presence of an extract of C. monspe / iensis at a final concentration of 0.01% by weight relative to the final volume of culture. melanocytes.
- it is the extract of C. monspe / iensis as prepared according to Example 1a), under the conditions described in Example 6.
- the extract of C. monspe / iensis is useful for reducing pigmentation spots on the skin, helping to increase the uniformity of the complexion.
- the extract is considered to be effective in reducing pigment spots when it reduces the overall melanin level by at least 40%, advantageously by at least 55% and more advantageously by at least 60%.
- this is a measurement carried out in B16 melanocytes cultured in the presence of an extract of C. monspe / iensis at a final concentration of 0.01% by weight relative to the final volume of culture of the melanocytes.
- it is the extract of C. monspe / iensis as prepared according to Example 1a), under the conditions described in Example 6.
- the use of the extract of C. monspe / iensis according to the invention is for increasing and / or maintaining tissue homeostasis in the scalp, advantageously in the follicle hairy, thus increasing the anchoring of the hair at the level of the scalp.
- the extract of C. monspe / iensis maintains and / or increases cell differentiation at the level of the scalp, advantageously still at the level of the hair follicle, by maintaining and / or increasing the gene and / or protein expression of ECMl at the level of the hair follicle.
- the extract of C. monspe / iensis can be used to reduce hair loss.
- the extract according to the invention can be all or part of the C. monspeliensis plant chosen from the whole plant, the aerial parts, the stem, the leaves, the trichomes, the branches, the flowers, the seeds.
- it is an extract from the aerial parts.
- the term "aerial parts" is understood here to mean the leaves, stems, branches and flowers.
- the extract of C. monspeliensis is an extract of leaves.
- the extract can be obtained by any extraction method known to those skilled in the art chosen from hot decoction, grinding, including grinding with ultrasound, using a mixer, maceration, extraction with water. under subcritical conditions or extraction using a solvent.
- the extract will be obtained by maceration.
- the extraction will not be carried out by co-extraction with supercritical CO 2 in the presence of a solvent, in particular a solvent composed of triglycerides of plant origin, more particularly a solvent composed of C8-C10 triglycerides.
- a solvent in particular a solvent composed of triglycerides of plant origin, more particularly a solvent composed of C8-C10 triglycerides.
- the extraction will not be carried out with supercritical CO 2 or by hydrodistillation assisted by microwave, in particular by hydrodistillation under vacuum by microwave.
- extraction under “subcritical conditions” is meant extraction in the presence of water, under conditions of temperature greater than 100 ° C. and of pressure less than or equal to 22.1 MPa (221 bars), such that the water remains at the liquid state but has a viscosity and a surface tension lower than that of water at room temperature, increasing its dielectric constant.
- the extraction pressure will be between 10 MPa (100 bar) and 25 MPa (250 bar).
- the extraction can be carried out from dry or fresh plant material, advantageously dry, in an amount of 0.1% to 30% by weight, advantageously from 1% to 20%, very advantageously from 5% to 15%, and again more advantageously 10%, by weight of plant material relative to the total weight of the plant material and of the extraction solvent.
- the extraction can be carried out at a temperature ranging from 4 ° C to 300 ° C, including ambient temperature, that is to say a temperature of 20 ° C.
- the extraction will be carried out at a temperature of 60 ° C to 90 ° C, preferably from 70 ° C to 85 ° C, still preferably at a temperature of 80 ° C.
- the extraction can be carried out during a period of a few seconds to 24 hours, preferably from 1 minute to 12 hours, again preferably during a period from 5 minutes to 5 hours, and again advantageously during a period from 15 minutes to 2 hours.
- the solvent may be chosen from water, or a mixture of solvent, preferably a practical polar solvent, and advantageously in water, an alcohol, a glycol, a polyol, a water / alcohol, water / glycol or water mixture.
- / polyol such as water mixed with ethanol, glycerol and / or butylene glycol and / or other glycols such as xylitol and / or propanediol, etc.
- 99/1 to 1/99 (w / w) advantageously in water as the sole solvent.
- the extract is obtained by aqueous extraction.
- extract obtained by aqueous extraction means any extract obtained by extraction with an aqueous solution containing more than 60% by weight, advantageously at least 70% by weight, in particular at least 80% by weight , more particularly at least 90% by weight, in particular at least 95% by weight, of water relative to the total weight of the aqueous solution, even more advantageously not containing glycol and / or polyol and in particular not containing alcohol, more particularly containing only water.
- the extract of Cistus monspe / iensis according to the invention is an aqueous extract obtained in water or a mixture of water with a solvent chosen from the group consisting of an alcohol, a glycol, a polyol and their mixture. , advantageously in water as the sole solvent.
- the extraction is not carried out with boiling water.
- the extract of Cistus monspe / iensis according to the invention is a water-soluble extract. It is therefore not a lipid extract. In particular it does not contain essential oils or lipid fraction. Even more advantageously, the extract is not solidified in the form of wax, in particular it is not mixed with an oil of vegetable origin, more particularly composed of C16-C18 triglycerides.
- the extract is obtained by extraction in a mixture of propanediol and water in respective proportions (80:20; v / v). In yet another alternative embodiment, the extract is obtained by extraction in a mixture of ethanol and water in respective proportions (80:20; v / v).
- the extraction may be carried out in the presence of a nonionic surfactant, preferably chosen from lauryl glucoside sold under the name Plantacare® 1200UP by BASF or alternatively caprylyl / capryl glucoside (Plantacare® 810 UP), preferably caprylyl / capryl glucoside (Plantacare® 810 UP).
- a nonionic surfactant preferably chosen from lauryl glucoside sold under the name Plantacare® 1200UP by BASF or alternatively caprylyl / capryl glucoside (Plantacare® 810 UP), preferably caprylyl / capryl glucoside (Plantacare® 810 UP).
- the concentration by weight of the nonionic surfactant may be between 0.5% and 5%, advantageously between 0.5 and 1%, more advantageously it will be 1% by weight relative to the total weight of the extract.
- the extraction will be carried out in water under subcritical conditions, at a temperature ranging from 100 ° C to 300 ° C, advantageously from 120 ° C to 250 ° C.
- the extraction can be carried out at a single given temperature or at successive increasing temperatures.
- the extraction will be carried out at a single temperature of 120 ° C.
- it will be carried out according to a gradient of three increasing temperatures between 100 ° C and 200 ° C, such as 120 ° C, 140 ° C then 160 ° C or 110 ° C, 130 ° C then 150 ° C , or 120 ° C, 145 ° C then 170 ° C.
- the extract of C. monspeliensis will be obtained by maceration in water as the sole solvent.
- the extract will be obtained from an amount of 10% by weight of the dried aerial parts of C. monspeliensis relative to the total weight of the plant and of the solvent, macerated in water as the sole solvent, at a temperature of 80 ° C for a period of 1 hour.
- the extract obtained is separated by centrifugation and the supernatant filtered (0.20 pm), under the conditions described in example la).
- the extract will be obtained from an amount of 20% by weight of the dried aerial parts of C. monspeliensis relative to the total weight of the plant and of the solvent, macerated in water as the sole solvent, at a temperature of 80 ° C for a period of 1 hour.
- the extract obtained is separated by centrifugation and the supernatant filtered (0.20pm), under the conditions described in Example 1b).
- the extract will be obtained from an amount by weight of 10% of dried aerial parts of C. monspe / iensis relative to the total weight of the plant and of the solvent, macerated in a water mixture. / propanediol (20:80; v / v), at a temperature of 4 ° C during a period of 2 hours.
- the extract obtained is separated by centrifugation and the supernatant filtered (0.20pm), under the conditions described in example le).
- the extract will be obtained from an amount by weight of 10% of dried leaves of C. monspe / iensis relative to the total weight of the plant and of the solvent, macerated in water as the sole solvent, at a temperature of 4 ° C for a period of 24 hours.
- the extract obtained is separated by centrifugation and the supernatant filtered (0.20 pm), under the conditions described in Example 1d).
- the extract will be obtained from an amount by weight of 10% of the dried aerial parts of C. monspe / iensis relative to the total weight of the plant part and of the solvent, extracted in water under subcritical conditions at a temperature of 120 ° C under pressure of 250 bars (25MPa).
- the crude extract is decanted, centrifuged and then filtered (0.20pm), under the conditions of example le).
- the extract obtained is dried and atomized in the presence of maltodextrin.
- the maltodextrin is present in a concentration of between 70 and 90%, advantageously, between 70 and 80%, still advantageously between 75% and 80%, very advantageously the concentration of maltodextrin is 80% by weight relative to the total weight of the maltodextrin and extract according to the invention.
- the extract obtained after atomization is in the form of a powder.
- the extract of C. monspe / iensis according to the invention does not contain labdane (C20H38; molar mass 278.524 g / mol; case n ° 561-90-0) nor any of its labdanic derivatives and / or labdenenoic acid and / or its salts, in particular the alkali metal salts such as sodium and potassium salts, alkaline earth salts such as calcium salts and magnesium salts, ammonium salts, monomethylammonium, dimethylammonium, trimethylammonium and dicylohexylammonium salts.
- the alkali metal salts such as sodium and potassium salts
- alkaline earth salts such as calcium salts and magnesium salts
- ammonium salts monomethylammonium, dimethylammonium, trimethylammonium and dicylohexylammonium salts.
- the extract of C. monspe / iensis according to the invention does not contain labdanic derivatives and / or labdenenoic acid chosen from:
- labdanolic acid otherwise called labdanic acid (C20H36O3; molar mass 324.505 g / mol; case n ° 10267-24-0) or one of its salts;
- 1-Naphthalenepentanoic acid, 3,4,4a, 5,6,7,8,8a-octahydro-p, 2,5,5,8a- pentamethyle, methyl ester, (4aS, 8aS) (case n ° 248581 -34-2, C 2 IH3 6 0 2 , molar mass: 320.27 g / mol) or one of its salts;
- R 1 represents a group -CH 2 OH, -COOR 6 , or -COOX
- X representing the base which can form a salt
- R 6 represents a hydrogen atom or an alkyl group having from 1 to 3 carbon atoms
- R 2 to R 5 independently of one another represent a hydrogen atom or a methyl group
- the extract of C. monspeliensis according to the invention does not contain beta-endorphin.
- the extract of C. monspeliensis obtained in water as the sole solvent does not contain labdane or any one of its Labdanic derivatives and / or of its salts, advantageously chosen from those mentioned above.
- the extract of C. monspeliensis obtained in water as the sole solvent more advantageously the extract of the aerial parts prepared under the conditions of example 1a), does not contain beta-endorphin.
- the cosmetic composition comprising the extract of C. monspeliensis, advantageously obtained in water as the sole solvent, still advantageously the extract of the aerial parts prepared under the conditions of Example 1a), does not contain labdane nor any of its labdanic derivatives and / or of its salts, advantageously chosen from those mentioned above.
- the cosmetic composition comprising the extract of C. monspeliensis, advantageously obtained in water as the sole solvent, still advantageously the extract of the aerial parts prepared under the conditions of Example 1a), does not contain beta -endorphine.
- the extract according to the invention can be used alone or included in a cosmetic composition. If the extract is used alone as an active cosmetic ingredient, it is advantageously dissolved in an aqueous solution comprising glycerin, advantageously present at a concentration of 60% to 90%, still advantageously from 70% to 85%, very advantageously at a concentration of 80% by weight relative to the total weight of the hydroglycerin solution comprising the extract.
- the extract of C. monspeliensis according to the invention is not used in combination with Thymus hyemaiis or one of its extracts. Even more advantageously, the cosmetic composition according to the invention does not contain Thymus hyemaiis or one of its extracts.
- the extract will be dissolved and / or diluted in a solvent, in particular a polar solvent, such as water, an alcohol, a polyol, a glycol, such as pentylene glycol and / or butylene glycol and / or hexylene glycol and / or caprylyl glycol, or a mixture thereof, preferably a hydroglycolic mixture, still preferably containing a glycol chosen from hexylene glycol, caprylyl glycol and mixtures thereof.
- a solvent in particular a polar solvent, such as water, an alcohol, a polyol, a glycol, such as pentylene glycol and / or butylene glycol and / or hexylene glycol and / or caprylyl glycol, or a mixture thereof, preferably a hydroglycolic mixture, still preferably containing a glycol chosen from hexylene glycol, caprylyl glycol and mixtures thereof.
- the extract obtained is diluted and / or soluble in an aqueous solution containing hexylene glycol, in particular containing between 0.1 and 10% by weight of the hexylene glycol, preferably between 0.5 and 5% by weight. of hexylene glycol, relative to the total weight of the cosmetic ingredient.
- the extract obtained is diluted and / or soluble in an aqueous solution containing caprylyl glycol, in particular containing between 0.01 and 5% by weight of caprylyl glycol, preferably between 0.1 and 1% by weight of caprylyl glycol, relative to the total weight of the aqueous solution comprising the extract.
- the extract of C. monspe / iensis may be included in a cosmetic composition comprising at least one cosmetically acceptable excipient.
- cosmetically acceptable excipient means a cosmetic excipient or non-irritant for the skin, which does not induce an allergic response, and is chemically stable.
- the excipient (s) may be chosen from surfactants and / or emulsifiers, preservatives, buffering agents, chelating agents, denaturants, opacifying agents, pH adjusters, reducing agents, stabilizing agents, thickeners, gelling agents, film-forming polymers, fillers, mattifying agents, glossing agents, pigments, dyes, perfumes, and mixtures thereof.
- CTFA Cosmetic Ingredient Handbook, Second Edition (1992) describes various cosmetic excipients suitable for use in the present invention.
- the excipient (s) are chosen from the group comprising polyglycerols, esters, polymers and cellulose derivatives, lanolin derivatives, phospholipids, lactoferrins, lactoperoxidases, sucrose-based stabilizers, vitamin E and its derivatives, xanthan gums, natural and synthetic waxes, vegetable oils, triglycerides, unsaponifiables, phytosterols, silicones, protein hydrolysates, betaines, aminoxides, plant extracts, sucrose esters , titanium dioxides, glycines, and parabens, and more preferably from the group consisting of steareth-2, steareth-21, glycol-15 stearyl ether, cetearl alcohol, phenoxyethanol, methylparaben, ethylparaben, propylparaben, butylparaben, butylene glycol, caprylyl glycol, natural tocopherols, glycerin, dihydroxycet
- the cosmetic composition may be chosen from a solution, aqueous or oily, an aqueous cream or gel or an oily gel, in particular a shower gel, a milk, an emulsion, a microemulsion or a nanoemulsion, in particular oil-in-water or water -in oil or multiple or silicone, a mask, a serum, a lotion, a liquid soap, a shampoo, an ointment, a foam, a patch, an anhydrous product, preferably liquid, pasty or solid, for example in the form of make-up, stick or stick powders, in particular in the form of lipstick.
- it will be a cream or a serum.
- the cosmetic composition may also comprise active ingredients for strengthening the barrier function of the skin and / or the skin appendages, inducing a complementary or synergistic effect with the extract of C. monspe / iensis according to the invention, chosen from those which strengthen the barrier function and decrease the insensitive water losses and / or those which increase the water content of the skin and / or mucous membranes and / or stimulate the synthesis of aquaporin to improve the circulation of water in the cells .
- alkylcelluloses such as lecithins, sphingoid-based compounds, ceramides, phospholipids, cholesterol and its derivatives, glycosphingolipids, phytosterols (stigmasterol and beta-sitosterol, campesterol), essential fatty acids, 1-2 diacylglycerol, 4 - chromanone, pentacyclic triterpenes such as ursolic acid, petrolatum, lanolin, sugars in particular trehalose and its derivatives, rhamnose, fructose, maltose, lactose, erythritol, mannitol, D-xylose and glucose, adenosine and its derivatives, sorbitol, polyhydric alcohols, advantageously in C2-C6, and still more advantageously in C3-C6, such as glycerin, propylene glycol, 1,3-butylene glycol, dipropylene glycol, diglycerin,
- active agents may be present in the composition, such as anti-aging active agents and / or whitening active agents, and / or anti-pollution active agents and / or promoting the radiance of the complexion.
- the extract of C. monspe / iensis will be present in the cosmetic composition in a concentration of 0.0001% to 20% by weight, preferably from 0.001% to 5% by weight, again preferably from 0.01% to 3% by weight relative to the total weight of the cosmetic composition.
- the cosmetic composition comprising the extract of C. monspe / iensis according to the invention can therefore be used to increase and / or maintain tissue homeostasis in the skin and / or mucous membranes and / or cutaneous appendages.
- Said composition is thus used to maintain and / or increase the gene and / or protein expression of ECMl and / or involucrine in order to increase and / or maintain the barrier function at the level of the skin and / or cutaneous appendages. and / or cell differentiation in the skin and / or mucous membranes and / or cutaneous appendages.
- said cosmetic composition is not for increasing and / or maintaining cell growth or proliferation, or cell division. In a particular embodiment, the cosmetic composition is not for increasing and / or maintaining the synthesis of ATP.
- said cosmetic composition does not comprise an alginate, nor an algin, nor a hydrolyzed algin, nor a plant extract chosen from Lavandula stoechas, Helichrysum italicum and their mixtures.
- a second subject of the invention relates to a non-therapeutic cosmetic care method comprising the administration by topical or oral route, preferably the topical application, of an extract of C. monspe / iensis or of a cosmetic composition. comprising to increase and / or maintain tissue homeostasis in the skin and / or mucous membranes and / or cutaneous appendages.
- the cosmetic care process advantageously makes it possible to increase and / or maintain the barrier function at the level of the skin and / or the cutaneous appendages and / or to increase the cellular differentiation at the level of the skin and / or mucous membranes and / or cutaneous appendages, maintaining and / or increasing the gene and / or protein expression of involucrine and / or ECM1.
- the cosmetic care method comprises the topical application of the extract of C. monspe / iensis or of the cosmetic composition comprising it on all or part of the face and / or the body and / or scalp and / or skin appendices and / or mucous membranes chosen from the legs, hands, thighs, belly, Vietnameselleté, neck, arms, torso, back, hair, face, in particular the eye area, advantageously the neckline and / or the face, and in particular the eye area, also advantageously the eye area.
- the invention also relates to a cosmetic treatment method for increasing and / or maintaining tissue homeostasis in the skin and / or mucous membranes and / or cutaneous appendages of an individual who needs it.
- a cosmetic composition containing the extract of Cistus monspeliensis according to the invention in an amount effective to increase and / or maintain the tissue homeostasis, and / or increase and / or maintain gene and / or protein expression of involucrine and / or ECM1, and / or increase and / or maintain barrier function and / or cell differentiation, and / or increase and / or maintain tissue renewal and / or improve the surface appearance and / or reduce hair loss, and / or increase the radiance of the complexion and / or reduce water loss and / or prevent dehydration of this area of skin and / or mucosa and / or cutaneous appendages.
- a third subject of the invention relates to the extract of C. monspeliensis according to the invention or a dermatological or pharmaceutical composition comprising it for its use for the prevention and / or treatment of diseases induced by a decrease in expression ECM1 gene and / or protein, advantageously lichen sclerosus or lipoido-proteinosis, and / or for the prevention and / or treatment of scars.
- the extract is included in the dermatological or pharmaceutical composition in a concentration of 0.0001% to 20% by weight, preferably from 0.001% to 5% by weight, still preferably from 0.01% to 3 % by weight relative to the total weight of the composition.
- the dermatological composition or the pharmaceutical composition will comprise at least one dermatologically or pharmaceutically acceptable excipient.
- the extract of C. monspeliensis or the dermatological or pharmaceutical composition comprising it is applied topically to all or part of the face and / or of the body and / or of the scalp and / or skin appendages and / or mucous membranes chosen from the legs, hands, thighs, stomach, Vietnameselleté, neck, arms, torso, back, hair, face, especially around the eyes , advantageously the neckline and / or the face and in particular the eye area, more preferably the eye area.
- the extract of C. monspeliensis is an extract of the aerial parts of C. monspeliensis, more advantageously an extract of leaves. Still advantageously, the extract is an aqueous extract obtained in water as the sole solvent.
- Example 1a An amount of 10% by weight of dried aerial parts of the plant C. monspeliensis, relative to the total weight of the plant part and of the solvent, was macerated in water as the sole solvent at a temperature of 80 ° C during a period of 1 hour. The extract obtained was separated by centrifugation and the supernatant was filtered (0.20pm). The extract is in liquid form.
- Example 1b An amount of 20% by weight of dried aerial parts of the plant C. monspeliensis, relative to the total weight of the plant part and of the solvent, was macerated in water as the sole solvent at a temperature of 80 ° C during a period of 1 hour. The extract obtained was separated by centrifugation and the supernatant was filtered (0.20pm). The extract is in liquid form.
- Example 1e An amount of 10% by weight of dried aerial parts of the plant C. monspe / iensis, relative to the total weight of the plant part and of the solvent, was macerated in a water / propanediol mixture (20:80 ; v / v) as the sole solvent at a temperature of 4 ° C for a period of 2 hours. The extract obtained was separated by centrifugation and the supernatant was filtered (0.20pm). The extract is in liquid form.
- Example 1d An amount of 10% by weight of leaves relative to the total weight of the plant part and of the solvent was macerated in water as the sole solvent at a temperature of 4 ° C. during a period of 24 hours. The extract obtained was separated by centrifugation and the supernatant was filtered (0.20pm). The extract is in liquid form.
- Example le An amount of 10% by weight of the dried aerial parts of the plant C. monspe / iensis relative to the total weight of the plant part and of the solvent was extracted into water under subcritical conditions, at a temperature of 120 ° C under pressure of 250 bars. The crude extract is decanted, centrifuged and then filtered. The extract is in liquid form.
- Each of these extracts described above can then be dried and atomized in the presence of maltodextrin (from 70% to 90% by weight, advantageously 80% by weight, relative to the total weight of the maltodextrin and the extract).
- the extract obtained after atomization will be in the form of a powder.
- Example 2 Increase in gene and protein expression of the ECM1 marker in the presence of an extract of C. monspe / iensis
- RNAs were extracted with the NucleoSpin 96 RNA kit (Machery-Nagel GmbH & Co KG). The quantification and the quality of the total RNAs were controlled by measuring the optical densities at 260 and 280 nm.
- the expression of the ECM1 gene was quantified by qRT-PCR.
- the messenger mRNAs were transcribed into cDNAs with specific oligonucleotides (SYBR Green) using a thermocycler (LightCycler®480 I Master System (Roche Molecular Diagnostics).
- the ACTB (Actin B) and EEF1A1 (Eukaryotic Translation Elongation) genes Factor 1 Alpha 1) were used as reference genes for the normalization of the results, the fluorescence was measured at each amplification cycle and the relative quantification was carried out with the Ct method after drawing up the calibration curve.
- the extract of C. monspe / iensis increased the gene expression of ECMl by at least 43% compared to the control, showing its ability to increase cell differentiation, thus participating in tissue homeostasis.
- the cells were then harvested and then lysed with a specific lysis buffer in order to carry out the immuno-localization (Western Blot).
- the total protein concentration has been determined by the BCA method, and each condition is deposited at the same concentration.
- the proteins were identified by capillary electrophoresis (ProteinSimple, USA) using a primary anti-ECM1 antibody and immunolocalized using a conjugated secondary antibody coupled to peroxidase. The results were quantified using Compass Software (version 2.7.1 (ProteinSimple)), and reported to the untreated control (Control (without extract)).
- the extract of C. monspe / iensis increased by at least 31% the expression of ECMl in keratinocytes in culture, confirming the ability of the extract to increase cell differentiation and consequently the tissue homeostasis.
- the extract of C. monspeliensis increased the synthesis of involucrine by at least 168% in cultured keratinocytes.
- the extract of C. monspeliensis according to the invention is effective in increasing the barrier function of the skin and / or of the cutaneous appendages.
- Example 5 Examples of cosmetic or dermatological compositions comprising an extract of Cistus monsoeliensis
- the percentages are expressed by weight relative to the total weight of the cosmetic formulation in table 5.
- the percentages are expressed by weight relative to the total weight of the cream (% w / w) in Table 6.
- the cream is prepared by the usual methods in the field well known to those skilled in the art, by mixing the 5 phases.
- EXAMPLE 6 Increase in Radiance and Uniformity of the Complexion Protocol: B16 melanocytes were cultured in a standard culture medium comprising fetal calf serum for a period of 3 days at a temperature of 37 ° C (5% CO2). The medium was renewed identically with the addition of the extract of C. monspe / iensis according to Example 1a) at a final concentration of 0.01% by weight relative to the final volume of the medium or without extract (Medium control). After a period of 3 days of culture, the total amount of melanin was measured by optical density at 475 nm. The tests were carried out in triplicate and the results expressed in% average compared to the control (Culture without extract of C. monspe / iensis) (ET: Standard deviation). Statistical analysis was performed by student test (Sigmaplot TM).
- the extract reduced the total amount of melanin by at least 55% in the melanocytes analyzed, demonstrating the effect of the extract on the uniformity and radiance of the complexion.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1873817A FR3090375B1 (fr) | 2018-12-21 | 2018-12-21 | Nouvelles utilisations cosmétiques et dermatologiques d’un extrait de Cistus monspeliensis |
PCT/FR2019/052991 WO2020128223A1 (fr) | 2018-12-21 | 2019-12-10 | Nouvelles utilisations cosmétiques et dermatologiques d'un extrait de cistus monspeliensis |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3897868A1 true EP3897868A1 (fr) | 2021-10-27 |
Family
ID=66676759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19842805.4A Pending EP3897868A1 (fr) | 2018-12-21 | 2019-12-10 | Nouvelles utilisations cosmétiques et dermatologiques d'un extrait de cistus monspeliensis |
Country Status (7)
Country | Link |
---|---|
US (1) | US20220241181A1 (zh) |
EP (1) | EP3897868A1 (zh) |
JP (1) | JP2022511023A (zh) |
KR (1) | KR20210105880A (zh) |
CN (1) | CN113164797B (zh) |
FR (1) | FR3090375B1 (zh) |
WO (1) | WO2020128223A1 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111557878A (zh) * | 2020-06-28 | 2020-08-21 | 无锡简玺生物科技有限公司 | 一种含类人胶原蛋白和聚繖岩蔷嶶提取物的精华及制备方法 |
KR20240027604A (ko) * | 2021-05-20 | 2024-03-04 | 록 옵코 엘엘씨 | 비타민 c 화합물을 함유하는 화장품 조성물 및 그의 사용 |
FR3129830A1 (fr) | 2021-12-07 | 2023-06-09 | Pierre Fabre Dermo-Cosmetique | Extrait de Cistus monspeliensis et compositions le comprenant pour apaiser la peau |
FR3135205A1 (fr) | 2022-05-09 | 2023-11-10 | Pierre Fabre Dermo-Cosmetique | Extrait de cistus monspeliensis et compositions le comprenant pour favoriser la cicatrisation et la reparation des lesions cutanees |
CN115671002B (zh) * | 2022-11-23 | 2024-02-20 | 广州睿森生物科技有限公司 | 一种抗皱滋养祛痘组合物及其应用 |
CN117503626B (zh) * | 2023-11-09 | 2024-04-16 | 植物医生(广东)生物科技有限公司 | 植物来源的防晒增效组合物、防晒产品、制备方法和应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2818547B1 (fr) | 2000-12-22 | 2006-11-17 | Oreal | Nouveaux derives c-glycosides et utilisation |
FR2819718B1 (fr) * | 2001-01-22 | 2005-02-25 | Codif Internat Sa | Produit cosmetique |
JP3942177B2 (ja) | 2003-04-11 | 2007-07-11 | 高砂香料工業株式会社 | 細胞賦活剤 |
JP2005008574A (ja) | 2003-06-19 | 2005-01-13 | Takasago Internatl Corp | コラーゲン産生促進剤 |
FR2868307B1 (fr) * | 2004-04-01 | 2008-03-14 | Courtage Et De Diffusion Codif | Utilisation de beta-endorphine pour le traitement des rides |
GB2443388A (en) | 2006-10-30 | 2008-05-07 | Reckitt & Colmann Prod Ltd | Acne treatment |
ES2340352B1 (es) * | 2008-06-06 | 2011-05-10 | Pedro Enrique Alonso Hernandez | Unguento o liquido de aplicacion topica para las heridas. |
JP5678373B2 (ja) | 2010-02-12 | 2015-03-04 | 国立大学法人 筑波大学 | Atp産生促進剤、およびその利用 |
-
2018
- 2018-12-21 FR FR1873817A patent/FR3090375B1/fr active Active
-
2019
- 2019-12-10 US US17/416,049 patent/US20220241181A1/en active Pending
- 2019-12-10 CN CN201980078067.8A patent/CN113164797B/zh active Active
- 2019-12-10 WO PCT/FR2019/052991 patent/WO2020128223A1/fr unknown
- 2019-12-10 KR KR1020217015887A patent/KR20210105880A/ko unknown
- 2019-12-10 JP JP2021531693A patent/JP2022511023A/ja active Pending
- 2019-12-10 EP EP19842805.4A patent/EP3897868A1/fr active Pending
Also Published As
Publication number | Publication date |
---|---|
FR3090375B1 (fr) | 2021-10-22 |
CN113164797B (zh) | 2024-05-28 |
WO2020128223A1 (fr) | 2020-06-25 |
FR3090375A1 (fr) | 2020-06-26 |
JP2022511023A (ja) | 2022-01-28 |
US20220241181A1 (en) | 2022-08-04 |
KR20210105880A (ko) | 2021-08-27 |
CN113164797A (zh) | 2021-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3897868A1 (fr) | Nouvelles utilisations cosmétiques et dermatologiques d'un extrait de cistus monspeliensis | |
EP3612276A1 (fr) | Utilisation d'un extrait de péricarpe de nephelium lappaceum pour hydrater la peau et/ou les muqueuses | |
WO2020084259A1 (fr) | Nouvelles utilisations cosmetiques et dermatologiques d'un extrait du champignon inonotus obliquus | |
WO2015052082A1 (fr) | Utilisation cosmétique et/ou dermatologique d'un extrait d'hamamelis virginiana | |
WO2018203000A1 (fr) | Utilisation d'un extrait de nephelium lappaceum pour augmenter la fermeté de la peau et/ou des muqueuses | |
EP2978503B1 (fr) | Utilisation cosmetique d'un extrait de polygonum bistorta | |
WO2018091825A1 (fr) | Utilisation cosmétique, nutraceutique ou pharmaceutique préférentiellement dermatologique d'un extrait de feuilles de la plante lansium domesticum pour diminuer la pigmentation de la peu et/ou des annexes cutanées | |
WO2017178751A1 (fr) | Utilisation cosmétique d'un extrait de khaya senegalensis | |
FR3061015B1 (fr) | Utilisation cosmetique d'un extrait de corchorus olitorius | |
FR3106756A1 (fr) | Utilisation cosmétique, nutraceutique ou dermatologique d'un extrait deTamarindus indicaL. et / ou d’une composition le comprenant | |
EP3237072B1 (fr) | Utilisation d'un extrait de lythrum salicaria | |
CH694904A5 (fr) | Utilisation d'un extrait de Rhodiola crenulata, par voie topique. | |
FR3010314A1 (fr) | Utilisation cosmetique ou dermatologique d'un extrait de tapirira guyanensis | |
EP4009940A1 (fr) | Nouvelle utilisation cosmétique d'un extrait d'epilobium angustifolium | |
FR3103386A1 (fr) | Nouvelle utilisation cosmétique d’un extrait glycoprotéique de Prunus dulcis | |
FR3099701A1 (fr) | Nouvelle utilisation cosmétique d’une combinaison d’oenothéine-B et de quercétine-3-O-glucuronide | |
FR3067940A1 (fr) | Utilisation cosmetique ou pharmaceutique d'un extrait d'adiantum capillus-veneris l. pour augmenter l'hydratation de la peau et/ou des muqueuses | |
FR3010307A1 (fr) | Utilisation cosmetique ou dermatologique d'avicularine | |
FR3076734A1 (fr) | Nouvelle utilisation cosmetique d'un extrait de nephelium lappaceum | |
WO2019020920A2 (fr) | Extrait aqueux de momordica cochinchinensis pour maintenir et/ou augmenter l'expression des kindlines de la peau et des muqueuses | |
FR3052358A1 (fr) | Nouvelle utilisation d'un extrait d'orthosiphon stamineus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210721 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20231114 |